Ascendis Settles YUVIWEL Litigation with BioMarin — 20% U.S. Royalty Through 2030
ASND sits 41% above its 52-week low of $186.054.
Summary
Ascendis Pharma and BioMarin signed a binding term sheet to settle all YUVIWEL litigation. Ascendis gets an unrestricted worldwide license; BioMarin gets 20% U.S. and 18% EU/South Korea/Brazil royalties through May 2030.
Key Events · Legal and Risk Events · ASND
-
Global Litigation Settlement Reached
Ascendis and BioMarin entered a binding term sheet resolving all litigation and disputes over YUVIWEL (navepegritide) and related products.
-
Royalty Terms Quantified
Ascendis will pay BioMarin 20% of U.S. net sales and 18% of net sales in the EU, South Korea, and Brazil from first commercial sale through May 20, 2030.
-
Unrestricted Worldwide License Granted
BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize navepegritide-related products without restriction.
-
BioMarin Concessions
BioMarin waives certain regulatory rights and exclusivities, dismisses all proceedings, and provides a covenant not to sue on covered intellectual property.
Analysis · ASND · Life Sciences
Ascendis resolves all litigation with BioMarin over YUVIWEL (navepegritide) via a binding term sheet. The deal removes a major legal overhang and secures an unrestricted worldwide license to develop and commercialize the product. In exchange, Ascendis pays BioMarin a 20% royalty on U.S. net sales and 18% in the EU, South Korea, and Brazil through May 20, 2030. The royalty is a meaningful cost of sales, but the certainty of market access and elimination of litigation risk outweighs the margin impact for a product already showing early commercial traction.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASND was trading at $263.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4B. The 52-week trading range was $186.05 to $282.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.